Scholarlink

Objective <p>To evaluate the associations of plasma EBV-DNA and tumor EBV status with clinical outcomes in patients with AIDS-related non-Hodgkin lymphoma (ARL).</p> Methods <p>We retrospectively analyzed ARL patients diagnosed at Shanghai Public Health Clinical Center between 2013 and 2021. Tumor EBV status was determined by EBV-encoded RNA (EBER) in situ hybridization, and plasma EBV-DNA was quantified using real-time PCR. Survival outcomes were evaluated using Kaplan–Meier analysis and Cox regression. Longitudinal EBV-DNA patterns during chemotherapy were classified into four groups: persistently negative, persistently positive, clearance, and conversion.</p> Results <p>Among 183 ARL patients, 99 underwent tumor EBER testing with 45.5% (45/99) positivity. Survival analysis was performed in 85 ARL patients who received treatment. The 2-year overall survival (OS) did not differ by EBER status (positive: 63.2% vs. negative: 52.5%; HR 0.86, 95% CI 0.41–1.80; <i>p</i> = 0.695). Baseline plasma EBV-DNA was quantified in 52 patients, with 47 (90.4%) undergoing ≥ 4 tests during chemotherapy cycles. Baseline plasma EBV-DNA levels were not predictive of prognosis. However, detectable EBV-DNA during chemotherapy was associated with significantly inferior OS (<i>p</i> = 0.048) and remained an independent prognostic factor after adjustment. Longitudinal analysis showed no statistically significant survival differences among four EBV-DNA patterns (<i>p</i> = 0.074), but patients with persistently positive or conversion patterns exhibited poorer outcomes, while persistently negative or clearance patterns were associated with more favorable prognosis. Pairwise analysis confirmed significantly better survival in persistently negative compared with persistently positive patients (<i>p</i> = 0.016).</p> Conclusion <p>Dynamic monitoring of plasma EBV-DNA during chemotherapy provides important prognostic information in ARL. Persistent or newly detectable EBV-DNA identifies patients at higher risk of poor outcomes, supporting the clinical utility of longitudinal EBV-DNA assessment for risk stratification and treatment guidance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma EBV DNA dynamics during chemotherapy as a prognostic biomarker in AIDS-related non-Hodgkin lymphoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月3日

查看全文
  • Zhenyan Wang,
  • Li Liu,
  • Jun Chen,
  • Tangkai Qi,
  • Wei Song,
  • Jianjun Sun,
  • Yang Tang,
  • Shuibao Xu,
  • Junyang Yang,
  • Yinzhong Shen,
  • Renfang Zhang

摘要

Objective

To evaluate the associations of plasma EBV-DNA and tumor EBV status with clinical outcomes in patients with AIDS-related non-Hodgkin lymphoma (ARL).

Methods

We retrospectively analyzed ARL patients diagnosed at Shanghai Public Health Clinical Center between 2013 and 2021. Tumor EBV status was determined by EBV-encoded RNA (EBER) in situ hybridization, and plasma EBV-DNA was quantified using real-time PCR. Survival outcomes were evaluated using Kaplan–Meier analysis and Cox regression. Longitudinal EBV-DNA patterns during chemotherapy were classified into four groups: persistently negative, persistently positive, clearance, and conversion.

Results

Among 183 ARL patients, 99 underwent tumor EBER testing with 45.5% (45/99) positivity. Survival analysis was performed in 85 ARL patients who received treatment. The 2-year overall survival (OS) did not differ by EBER status (positive: 63.2% vs. negative: 52.5%; HR 0.86, 95% CI 0.41–1.80; p = 0.695). Baseline plasma EBV-DNA was quantified in 52 patients, with 47 (90.4%) undergoing ≥ 4 tests during chemotherapy cycles. Baseline plasma EBV-DNA levels were not predictive of prognosis. However, detectable EBV-DNA during chemotherapy was associated with significantly inferior OS (p = 0.048) and remained an independent prognostic factor after adjustment. Longitudinal analysis showed no statistically significant survival differences among four EBV-DNA patterns (p = 0.074), but patients with persistently positive or conversion patterns exhibited poorer outcomes, while persistently negative or clearance patterns were associated with more favorable prognosis. Pairwise analysis confirmed significantly better survival in persistently negative compared with persistently positive patients (p = 0.016).

Conclusion

Dynamic monitoring of plasma EBV-DNA during chemotherapy provides important prognostic information in ARL. Persistent or newly detectable EBV-DNA identifies patients at higher risk of poor outcomes, supporting the clinical utility of longitudinal EBV-DNA assessment for risk stratification and treatment guidance.